Novo Nordisk Rise as Wegovy Wins US Liver Disease Approval
Novo Nordisk is making headlines again. We saw its shares rise after the FDA approved Wegovy for a serious liver condition called MASH, or metabolic dysfunction-associated steatohepatitis. This recent approval is significant since Wegovy, previously known for weight management, can now also treat adults with moderate to advanced liver fibrosis. The news sparked optimism in the market, pushing Novo Nordisk’s stock up by as much as 5% at the opening.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
